Skip to main content

Parkinson’s Will Double by 2040: Are We Ready?

March 15, 2018

Scientists predict the number of people with Parkinson's in the world will double by 2042 to more than 12 million. In this webinar, our expert panelists review some reasons behind the growth and strategies for addressing the "Parkinson's Pandemic."

Webinar Details


Thursday, March 15, 2018


1 hr


12:00 pm ET

  • MJFF offers Continuing Medical Education (CME) credit for practicing health care professionals for each Third Thursday Webinar. Click the link in the Resource List after viewing the webinar to take the post-test survey and receive your CME credit.

    Date of Original Release: March 15, 2018
    Date Credit Expires: March 15, 2020

    Learning Objectives
    1. Discuss why the number of people with Parkinson's is projected to double by 2040. 
    2. List potential steps to limit the projected increase in Parkinson's. 
    3. Describe how we can increase access to care. 
    4. Summarize what people with Parkinson's can do today to live well, increase access to care and speed research.
    Target Audience

    This educational activity is designed for primary care physicians, family practice physicians, general medicine physicians, geriatricians, general neurologists, movement disorder specialists and any other health care practitioners who manage patients with Parkinson's disease.


    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and The Michael J. Fox Foundation for Parkinson's Research. The Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

    Oakstone Publishing, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


    Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing, LLC's planners, content reviewers, and editorial staff disclose no relevant commercial interests.


    Bastiaan Bloem, MD, PhD
    Medical Director
    Professor of Neurology
    Radboud University Nijmegen Medical Centre
    Research Grants: Netherlands Organization for Scientific Research, Parkinson Vereniging, Princess Beatrix Foundation, Parkinson Vereniging, National Parkinson Foundation, Hersenstichting, UCB, Abbvie
    Advisory Role: Zambon, Adamas, Kyowa Kirin
    Employment: Radboudumc
    Honoraria: Prof. Bloem has received fees for speaking at conferences from AbbVie, Zambon, Biall and Kyowa Kirin

    Ray Dorsey, MD, MBA
    David M. Levy Professor in Neurology
    Director, Center for Health + Technology (CHeT)
    University of Rochester Medical Center
    Nothing to disclose

    Dave Iverson
    Nothing to disclose

We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.